The Signicance Of HER-2, P53 And Ki-67 Expression In Colorectal Cancer

Objective:To detect the expression of HER-2 in colorectal cancer, to detect the expression of mutant p53,Ki-67 in colorectal cancer. To investigate the relationship between expression of HER-2, p53 and Ki-67 and colorectal cancer.Methods:Selected 68 cases of colorectal cancer, and 40 cases of peri-cancer mucosa as control. Envision two-step detection of HER-2 in colorectal cancer, of positive (++) cases by immunohistochemistry and then detected the amplification of HER-2 gene by fluorescence in situ hybridization(FISH), comparison of the sensitivity of the two detection methods. Envision two-step detection of expression of mutant p53, Ki-67 protein in colorectal cancer.Results:(1) HER-2 over-expression rate was 22.1%(15/68) detection of immunohistochemical, much higher than in peri-cancer mucosa 2.5%(1/40), and the difference has statistical significance (P<0.05). (2)The over-expression of HER-2 protein has no difference in gender, tumor size, location, differentiation, infiltrate depth, Duke's stage and lymph node metastasis in colorctal cancer, there is no statistical significance (P>0.05). but there is relationship between age and race and colorectal cancer, the over-expression rate of HER-2 is higher in age>60 group than in age<60 group and is higher in Uygur than in Hans (P<0.05). (3)13 cases of HER-2 positive (++) immunohistochemical was detected by fluorescence in situ hybridization the amplification of HER-2 gene,3 cases of positive results. (4)The expression of mutant p53 and Ki-67 was higher in colorectal cancer than in peri-cancer mucosa, and the difference has statistical significance (P<0.05). (5)The expression of mutant p53 is related with tumor location and the number of lymph node metastasis (P<0.05), Ki-67 has no correlation with any of clinicopathologic parameter. (6)There is no relationship between the expression of HER-2 and mutant p53 and Ki-67 protein(P>0.05).Conclusion:(1) The over-expression of HER-2, p53 and Ki-67 protein much higher in colorectal cancer than in peri-cancer mucosa, indicating that the three could be used as a biological factor of evaluating genesis and progression in colorectal cancer. (2) mutant p53 could be used in evaluating prognosis and screening patient with high-risk of metastasis. (3) fluorescence in situ hybridization and Immunohistochemistry combined detection of colorectal cancer the HER-2 expression could suggest of a targeted therapy to colorectal cancer.